{
    "clinical_study": {
        "@rank": "132980", 
        "arm_group": [
            {
                "arm_group_label": "BIIB017 (PEGylated Interferon Beta-1a)", 
                "arm_group_type": "Experimental", 
                "description": "Varying doses (63 mcg up to 188 mcg) of BIIB017 will be administered SC every other week for a total of 6 weeks."
            }, 
            {
                "arm_group_label": "BIIB017 (PEGylated Interferon Beta-1a) and Placebo", 
                "arm_group_type": "Experimental", 
                "description": "Varying doses (63 mcg up to 188 mcg) of BIIB017 will be administered SC every 4 weeks for a total of 6 weeks. To ensure blinding, each subject will receive placebo every other week."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo dose will be administered SC every other week for a total of 6 weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "The primary objectives are to identify the highest safe and well-tolerated dose and\n      frequency of BIIB017 (PEGylated Interferon Beta-1a) subcutaneous (SC), within the range of\n      63 to 188 mcg, when given every other week or every 4 weeks to healthy volunteers (HV)."
        }, 
        "brief_title": "A Multiple Dose Safety Study of PEG-IFN in Healthy Volunteers", 
        "completion_date": {
            "#text": "May 2008", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Key Inclusion Criteria:\n\n          -  Body Mass Index (BMI) of 18 to 35 kg/m2, inclusive, and a minimum body weight of 50.0\n             kg at screening.\n\n          -  All male subjects and female subjects of child-bearing potential must be willing and\n             able to practice effective birth control during the study and be willing and able to\n             continue contraception for 30 days after their last dose of study treatment.\n\n        Key Exclusion Criteria:\n\n          -  Abnormal screening and baseline blood and urine tests determined to be clinically\n             significant by the Investigator.\n\n          -  Hematologic or hepatic enzyme laboratory values that were outside the normal range.\n\n          -  History of severe allergic or anaphylactic reactions.\n\n          -  History of any clinically-significant (as determined by the Investigator) cardiac,\n             endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary,\n             neurologic, dermatologic, psychiatric, renal and/or other major disease, and/or\n             history of seizure disorder.\n\n          -  A family history of MS in a first-degree relative.\n\n          -  A fever (body temperature >38\u00b0C) or symptomatic viral or bacterial infection\n             (including upper respiratory infection) within 1 week prior to Day 1.\n\n          -  Abnormal ECG values as determined by the Investigator.\n\n          -  Positive test result for hepatitis C antibody, hepatitis B surface antigen (HBsAg),\n             or human immunodeficiency virus (HIV) antibody.\n\n          -  Female subjects who are considering pregnancy, currently pregnant or breastfeeding.\n\n          -  Subjects who received a tattoo or body piercing (including earring) within 60 days of\n             baseline or subjects who are considering getting a tattoo or body piercing (including\n             earring) in the next 60 days.\n\n          -  Use of any prescription or non-prescription medication that could inhibit bone marrow\n             or liver function.\n\n          -  Any previous treatment with any interferon product.\n\n          -  Participation in any other investigational drug study within the 4 weeks prior to Day\n             1 or within 5 half-lives of the investigational treatment, whichever is longer.\n\n          -  Treatment with the Flu Vaccine within 1 week prior to Day 1.\n\n        NOTE: Other protocol-defined inclusion/exclusion Criteria May Apply"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "69", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 25, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02125578", 
            "org_study_id": "105HV102"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "BIIB017 (PEGylated Interferon Beta-1a)", 
                    "BIIB017 (PEGylated Interferon Beta-1a) and Placebo", 
                    "Placebo"
                ], 
                "description": "Each participant will receive BIIB017 every other week or every 4 weeks.", 
                "intervention_name": "BIIB017 (PEGylated Interferon Beta-1a)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BIIB017 (PEGylated Interferon Beta-1a) and Placebo", 
                "description": "Each participant will receive placebo every other week or every 4 weeks.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Interferon-beta", 
                "Interferons", 
                "Interferon beta 1a"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "April 25, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Phoenix", 
                    "country": "United States", 
                    "state": "Arizona"
                }, 
                "name": "Research Site"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Dose-Ranging, Parallel-Group Study of PEGylated Interferon Beta-1a (BIIB017) in Healthy Volunteers", 
        "overall_official": {
            "affiliation": "Biogen Idec", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2008", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "The number of participants that experience Adverse Events (AEs)", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Day 71"
            }, 
            {
                "measure": "The number of participants that experience flu-like symptoms", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Day 71"
            }, 
            {
                "measure": "Participant assessment of injection site pain as measured by scores on a scale of 0 to 10, where 0 is no pain and 10 is extremely painful.", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Day 71"
            }, 
            {
                "measure": "Clinician assessment of the injection site for erythema as assessed by a scale 0 to 3, where 0 represents no erythema and 3 represents severe erythema", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Day 71"
            }, 
            {
                "measure": "Clinician assessment of the injection site for induration as assessed by a scale 0 to 3, where 0 represents no induration and 3 represents severe induration", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Day 71"
            }, 
            {
                "measure": "Clinician assessment of tenderness to digital pressure at the injection site will be assessed on a scale of 0 to 3, where 0 represents no tenderness and 3 represents severe tenderness", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Day 71"
            }, 
            {
                "measure": "Clinician assessment of temperature at the injection site will be assessed on a scale of 0 to 2, where 0 represents normal temperature and 2 represents hot.", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Day 71"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02125578"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "results_reference": {
            "PMID": "21680782", 
            "citation": "Hu X, Miller L, Richman S, Hitchman S, Glick G, Liu S, Zhu Y, Crossman M, Nestorov I, Gronke RS, Baker DP, Rogge M, Subramanyam M, Davar G. A novel PEGylated interferon beta-1a for multiple sclerosis: safety, pharmacology, and biology. J Clin Pharmacol. 2012 Jun;52(6):798-808. doi: 10.1177/0091270011407068. Epub 2011 Jun 16. Erratum in: J Clin Pharmacol. 2012 Sep;52(9):NP4-5."
        }, 
        "secondary_outcome": [
            {
                "measure": "AUC168h, area under the concentration-time curve", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 168 hours post dose"
            }, 
            {
                "measure": "Cmax, observed maximum serum concentration", 
                "safety_issue": "No", 
                "time_frame": "Up to 336 hours post-dose"
            }, 
            {
                "measure": "Tmax, time to reach maximum serum concentration", 
                "safety_issue": "No", 
                "time_frame": "Up to 336 hours post-dose"
            }, 
            {
                "measure": "Terminal t\u00bd, half-life of the terminal phase", 
                "safety_issue": "No", 
                "time_frame": "Up to 336 hours post-dose"
            }, 
            {
                "measure": "EAUC-336h, area under the concentration-time curve from time zero to 336 hours post-dose", 
                "safety_issue": "No", 
                "time_frame": "Up to 336 hours post-dose"
            }, 
            {
                "measure": "Emax, the peak concentration observed minus baseline concentration", 
                "safety_issue": "No", 
                "time_frame": "Day 1 and Day 29"
            }, 
            {
                "measure": "PD parameters of serum concentrations of neopterin", 
                "safety_issue": "No", 
                "time_frame": "Day 1 and Day 29"
            }
        ], 
        "source": "Biogen Idec", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Biogen Idec", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2008", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}